Pidilizumab

Drug Profile

Pidilizumab

Alternative Names: CT-011; MDV 9300

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator CureTech
  • Developer American Cancer Society; Beth Israel Deaconess Medical Center; CureTech; Georgia Regents University; Hadassah Medical Organization; Northwestern University; The Ohio State University Comprehensive Cancer Center; University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Acute myeloid leukaemia; Colorectal cancer; Diffuse large B cell lymphoma; Follicular lymphoma; Malignant melanoma; Multiple myeloma; Pancreatic cancer; Prostate cancer; Renal cell carcinoma
  • Phase I/II Glioma; Hepatitis C; Hepatocellular carcinoma

Most Recent Events

  • 28 Sep 2016 Medivation has been acquired by Pfizer
  • 16 Jun 2016 Efficacy and adverse events data from a phase I/II trial in Glioma released by Medivation
  • 08 Jun 2016 Ohio State University Comprehensive Cancer Center and CureTech reinitiates enrolment in a phase I/II trial for Multiple myeloma (Combination therapy, Second-line therapy or greater) in USA (NCT02077959)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top